scispace - formally typeset
F

Faith E. Davies

Researcher at University of Arkansas for Medical Sciences

Publications -  476
Citations -  33949

Faith E. Davies is an academic researcher from University of Arkansas for Medical Sciences. The author has contributed to research in topics: Multiple myeloma & Lenalidomide. The author has an hindex of 84, co-authored 441 publications receiving 29601 citations. Previous affiliations of Faith E. Davies include Hull Royal Infirmary & University of Birmingham.

Papers
More filters
Journal ArticleDOI

Guidelines for the use and interpretation of assays for monitoring autophagy

Daniel J. Klionsky, +1287 more
- 01 Apr 2012 - 
TL;DR: These guidelines are presented for the selection and interpretation of methods for use by investigators who aim to examine macroautophagy and related processes, as well as for reviewers who need to provide realistic and reasonable critiques of papers that are focused on these processes.
Journal ArticleDOI

High-dose chemotherapy with hematopoietic stem-cell rescue for multiple myeloma.

J. Anthony Child, +8 more
- 08 May 2003 - 
TL;DR: High-dose therapy with autologous stem-cell rescue is an effective first-line treatment for patients with multiple myeloma who are younger than 65 years of age and trend toward a greater survival benefit in the group of patients with a poor prognosis.
Journal ArticleDOI

Thalidomide and immunomodulatory derivatives augment natural killer cell cytotoxicity in multiple myeloma.

Faith E. Davies, +48 more
- 01 Jul 2001 - 
TL;DR: In vitro and in vivo data support the hypothesis that Thal may mediate its anti-MM effect, at least in part, by modulating NK cell number and function.
Journal ArticleDOI

Thalidomide and its analogs overcome drug resistance of human multiple myeloma cells to conventional therapy.

Teru Hideshima, +24 more
- 01 Nov 2000 - 
TL;DR: Clinical activity of Thal against MM that is refractory to conventional therapy is demonstrated and mechanisms of anti-tumor activity of thalidomide and its potent analogs (immunomodulatory drugs [IMiDs]) are delineated.
Journal ArticleDOI

Immunomodulatory drug CC-5013 overcomes drug resistance and is well tolerated in patients with relapsed multiple myeloma

Paul G. Richardson, +38 more
- 01 Nov 2002 - 
TL;DR: This study provides the basis for the evaluation of CC-5013, either alone or in combination, to treat patients with MM at earlier stages of disease and shows no significant somnolence, constipation, or neuropathy has been seen in any cohort.